You are here: Industry Insights > AstraZeneca

News List

AZ to file triple combination therapy for COPD pharmatimes
September 18, 2018
AstraZeneca has unveiled late-stage data backing use of its triple combination therapy PT010 in patients with chronic obstructive pulmonary disease (COPD).
EU approves AZ’ Bydureon BCise device pharmatimes
September 14, 2018
AstraZeneca says the European Commission has approved a new formulation of its once-weekly diabetes drug Bydureon.
AZ’ lupus therapy fails to hit the mark pharmatimes
September 14, 2018
AstraZeneca’s experimental drug anifrolumab has failed to hit targets in a late stage trial in patients with lupus.
AstraZeneca, Amgen’s tezepelumab wins ‘breakthrough’ status pharmatimes
September 13, 2018
AstraZeneca and Amgen’s tezepelumab has won breakthrough therapy status in the US for its potential to treat severe asthma without an eosinophilic phenotype.
AstraZeneca and Amgen receive breakthrough status for tezepelumab September 11, 2018
AstraZeneca and Amgen have received breakthrough therapy designation for tezepelumab to treat severe asthma, irrespective of an eosinophilic phenotype.
Olaparib, Durvalumab for I-SPY 2 Trial Announces americanpharmaceuticalreview
September 10, 2018
Quantum Leap Healthcare Collaborative (QLHC) announced that a new randomized, investigational treatment arm for the I-SPY 2 TRIAL includes the study of olaparib and durvalumab, two agents from AstraZeneca.
AstraZeneca gets FDA breakthrough therapy label for asthma treatment financialexpress
September 10, 2018
The drug, tezepelumab, is an injectable treatment that is expected to help a wider range of patients than existing asthma medicines like GlaxoSmithKline’s Nucala
PhaseBio nets $34M to advance Brilinta reversal agent, PAH drug fiercebiotech
September 06, 2018
PhaseBio is using its ELP platform to extend the half-life of proteins, peptides and other large molecules to create injectable drugs that can be administered less frequently.
Biohaven picks up AstraZeneca CNS drug, plans phase 3 fiercebiotech
September 06, 2018
Biohaven Pharmaceutical has licensed an experimental treatment of the neurodegenerative disorder multiple system atrophy (MSA) from AstraZeneca.
PARP inhibitors arrive in China via new priority review pathway pharmaceutical-technology
September 04, 2018
On August 24, AstraZeneca’s Lynparza (olaparib) was approved in China for maintenance therapy of platinum-sensitive recurrent ovarian cancer.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page